Publication details
Chronická myeloidní leukemie
| Title in English | Chronic myeloid leukemia |
|---|---|
| Authors | |
| Year of publication | 2016 |
| Type | Chapter of a book |
| MU Faculty or unit | |
| Citation | |
| Description | Chronic myeloid leukemia (CML) is a clonal myeloprolipherative disease characterized by the presence of the Philadelphia chromosome (Ph) and/or the fusion gene BCR-ABL1. Prognosis of the disease has improved substantially with the advent of tyrosine kinase inhibitors (TKI). Currently, five TKI are available: imatinib, nilotinib, dasatinib, bosutinib, and ponatinib. The chapter is focused on the CML treatment overview, with a particular interest in the newest drugs, such as bosutinib and ponatinib, characteristics. Practical experience with the new TKI is represented by the case report of the patient treated with ponatinib due to T315I mutation. |